Results 101 to 110 of about 5,504 (241)

Insulin‐reducing effect of adding imeglimin to ongoing dipeptidyl peptidase‐4 inhibitor therapy with multiple daily insulin injections (INSPIRE study)

open access: yesJournal of Diabetes Investigation, EarlyView.
ABSTRACT Introduction Simplifying multiple daily insulin injections (MDI) has attracted great interest in clinical practice. Although imeglimin shows good compatibility with dipeptidyl peptidase‐4 inhibitors (DPP‐4i), its effectiveness in patients treated with MDI remains unclear.
Atsushi Itsukaichi   +7 more
wiley   +1 more source

<i>N</i>-Alkyl Derivatives of Deoxynojirimycin (DNJ) as Antiviral Agents: Overview and Update. [PDF]

open access: yesMolecules
Checconi P   +10 more
europepmc   +1 more source

Association of glycation gap with hypoglycemia CGM indices, diabetic complications, and quality of life in Japanese type 2 diabetes patients

open access: yesJournal of Diabetes Investigation, EarlyView.
The difference between HbA1c and estimated A1c (eA1c) was defined as the GGap. The strong association of high GGap with CGM‐based hypoglycemic indices in type 2 diabetes is evident. The large GGap values, relying solely on HbA1c values during treatment, may increase the risk of hypoglycemia in patients with T2DM.
Satomi Sonoda   +13 more
wiley   +1 more source

Effects of age, sex, and renal function on bowel movement‐improving effects of Bifidobacterium bifidum G9‐1 on constipation in patients with type 2 diabetes mellitus and chronic kidney disease: A prespecified subgroup analysis of the BIRDIE study

open access: yesJournal of Diabetes Investigation, EarlyView.
This prespecified subgroup analysis of the BIRDIE study demonstrated that Bifidobacterium bifidum G9‐1 improved stool consistency, bowel movement, and quality of life in patients with type 2 diabetes mellitus, chronic kidney disease, and specifically in age ≥ 65 years, male, and those with eGFR ≥60 mL/min/1.73 m2.
Fuki Ikeda   +8 more
wiley   +1 more source

Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications

open access: yesJournal of Diabetes Investigation, EarlyView.
We conducted the single‐center, retrospective cohort study to evaluate and compare the risk of diabetic eye and kidney complications between newly initiated once‐daily liraglutide (0.9 mg) and once‐weekly dulaglutide (0.75 mg) in 331 Japanese patients with type 2 diabetes.
Aki Katamine   +4 more
wiley   +1 more source

Effects of esaxerenone add‐on therapy versus angiotensin II receptor blocker dose escalation on albuminuria and blood pressure in hypertensive patients with type 2 diabetes: An exploratory randomized study

open access: yesJournal of Diabetes Investigation, EarlyView.
ABSTRACT Aims Residual albuminuria remains a major clinical challenge in patients with type 2 diabetes mellitus and hypertension despite renin–angiotensin system inhibitor therapy. Esaxerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, reduces albuminuria; however, its effects on oxidative stress remain unclear.
Makoto Ohara   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy